Neurocrine Biosciences, Inc. (NASDAQ: NBIX) on Tuesday, plunged -1.15% from the previous trading day, before settling in for the closing price of $134.70. Within the past 52 weeks, NBIX’s price has moved between $92.61 and $148.37.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 34.77%. The company achieved an average annual earnings per share of 90.08%. With a float of $98.39 million, this company’s outstanding shares have now reached $98.70 million.
Considering the fact that the conglomerate employs 1400 people, you should pay attention to its efficiency factor.
Neurocrine Biosciences, Inc. (NBIX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Neurocrine Biosciences, Inc. is 2.24%, while institutional ownership is 93.45%. The most recent insider transaction that took place on May 31 ’24, was worth 37,278. In this transaction Chief Regulatory Officer of this company sold 273 shares at a rate of $136.55, taking the stock ownership to the 7,507 shares. Before that another transaction happened on May 29 ’24, when Company’s Director sold 40,000 for $133.46, making the entire transaction worth $5,338,564. This insider now owns 26,504 shares in total.
Neurocrine Biosciences, Inc. (NBIX) Recent Fiscal highlights
As on 3/31/2024, Multinational firm has announced its last quarter scores, in which it reported 0.95 earnings per share (EPS) for the period topping the consensus outlook (set at 0.78) by 0.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 90.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.00% during the next five years compared to 62.04% growth over the previous five years of trading.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Trading Performance Indicators
Neurocrine Biosciences, Inc. (NBIX) is currently performing well based on its current performance indicators. A quick ratio of 2.47 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.76. Likewise, its price to free cash flow for the trailing twelve months is 21.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.64, a number that is poised to hit 1.16 in the next quarter and is forecasted to reach 6.98 in one year’s time.
Technical Analysis of Neurocrine Biosciences, Inc. (NBIX)
Compared to the last year’s volume of 0.83 million, its volume of 0.64 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 31.06%. Additionally, its Average True Range was 4.10.
During the past 100 days, Neurocrine Biosciences, Inc.’s (NBIX) raw stochastic average was set at 25.28%, which indicates a significant increase from 14.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.27% in the past 14 days, which was higher than the 26.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $137.61, while its 200-day Moving Average is $126.99. Nevertheless, the first resistance level for the watch stands at $134.41 in the near term. At $135.66, the stock is likely to face the second major resistance level. The third major resistance level sits at $137.05. If the price goes on to break the first support level at $131.77, it is likely to go to the next support level at $130.38. Now, if the price goes above the second support level, the third support stands at $129.13.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Key Stats
Market capitalization of the company is 13.40 billion based on 100,637K outstanding shares. Right now, sales total 1,887 M and income totals 249,700 K. The company made 515,300 K in profit during its latest quarter, and 43,400 K in sales during its previous quarter.
